Novel Therapies for Neurofibromatosis Type 1-Associated Inoperable Plexiform Neurofibromas: A Systematic Literature Review

Previous PostIs the Assumption of Treatment Waning Applied Consistently Across Canada’s Drug Agency Reimbursement Reviews? Reviewing Pharmacoeconomic Assessments of Disease Modifying Therapies for the Treatment of Multiple Sclerosis
Next PostAre There Intersections in Evidence Requirements for Health Technology Assessment Agencies across North America, Europe and the Asia-Pacific?

© Copyright 2025 Initiate Consultancy is a limited company.
Registered in England and Wales. Reg No. 11903774 | Privacy Policy

Let’s discuss your purpose

hello@initiateconsultancy.com